These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 18497955)
1. Anticancer effect of SN-38 on colon cancer cell lines with different metastatic potential. Wallin A; Svanvik J; Holmlund B; Ferreud L; Sun XF Oncol Rep; 2008 Jun; 19(6):1493-8. PubMed ID: 18497955 [TBL] [Abstract][Full Text] [Related]
2. Schedule-dependent cytotoxicity of SN-38 in p53 wild-type and mutant colon adenocarcinoma cell lines. te Poele RH; Joel SP Br J Cancer; 1999 Dec; 81(8):1285-93. PubMed ID: 10604724 [TBL] [Abstract][Full Text] [Related]
3. Gene expression profile of colon cancer cell lines treated with SN-38. Wallin A; Francis P; Nilbert M; Svanvik J; Sun XF Chemotherapy; 2010; 56(1):17-25. PubMed ID: 20185912 [TBL] [Abstract][Full Text] [Related]
4. Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells. Oizumi S; Isobe H; Ogura S; Ishida T; Yamazaki K; Nishimura M; Kawakami Y; Dosaka-Akita H Anticancer Res; 2002; 22(6C):4029-37. PubMed ID: 12553028 [TBL] [Abstract][Full Text] [Related]
5. Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38. Hapke G; Yin MB; Wu J; Frank C; Rustum YM Int J Oncol; 2002 Nov; 21(5):1059-66. PubMed ID: 12370755 [TBL] [Abstract][Full Text] [Related]
6. Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells. Torigoe S; Ogata Y; Matono K; Shirouzu K Anticancer Res; 2009 Jun; 29(6):2083-9. PubMed ID: 19528468 [TBL] [Abstract][Full Text] [Related]
7. The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. LaBonte MJ; Manegold PC; Wilson PM; Fazzone W; Louie SG; Lenz HJ; Ladner RD Int J Cancer; 2009 Dec; 125(12):2957-69. PubMed ID: 19536776 [TBL] [Abstract][Full Text] [Related]
8. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance. Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336 [TBL] [Abstract][Full Text] [Related]
9. Equivalent effect of DNA damage-induced apoptotic cell death or long-term cell cycle arrest on colon carcinoma cell proliferation and tumour growth. Bhonde MR; Hanski ML; Notter M; Gillissen BF; Daniel PT; Zeitz M; Hanski C Oncogene; 2006 Jan; 25(2):165-75. PubMed ID: 16170360 [TBL] [Abstract][Full Text] [Related]
10. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Tse AN; Schwartz GK Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of Akt signaling by SN-38 induces apoptosis in cervical cancer. Liu Y; Xing H; Weng D; Song X; Qin X; Xia X; Weng Y; Liang F; Chen G; Han X; Ma X; Wang S; Zhou J; Xu G; Meng L; Ma D Cancer Lett; 2009 Feb; 274(1):47-53. PubMed ID: 18929442 [TBL] [Abstract][Full Text] [Related]
12. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Goldwasser F; Shimizu T; Jackman J; Hoki Y; O'Connor PM; Kohn KW; Pommier Y Cancer Res; 1996 Oct; 56(19):4430-7. PubMed ID: 8813137 [TBL] [Abstract][Full Text] [Related]
13. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines. Goldwasser F; Bae I; Fornace AJ; Pommier Y Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795 [TBL] [Abstract][Full Text] [Related]
14. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756 [TBL] [Abstract][Full Text] [Related]
15. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma. Chen TC; Su S; Fry D; Liebes L Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458 [TBL] [Abstract][Full Text] [Related]
16. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Jansen WJ; Zwart B; Hulscher ST; Giaccone G; Pinedo HM; Boven E Int J Cancer; 1997 Jan; 70(3):335-40. PubMed ID: 9033637 [TBL] [Abstract][Full Text] [Related]
17. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan. Tian L; Song S; Liu X; Wang Y; Xu X; Hu Y; Xu J Anticancer Drugs; 2014 Nov; 25(10):1175-81. PubMed ID: 25089570 [TBL] [Abstract][Full Text] [Related]
18. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Magrini R; Bhonde MR; Hanski ML; Notter M; ScherĂ¼bl H; Boland CR; Zeitz M; Hanski C Int J Cancer; 2002 Sep; 101(1):23-31. PubMed ID: 12209584 [TBL] [Abstract][Full Text] [Related]
19. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Davis PL; Shaiu WL; Scott GL; Iglehart JD; Hsieh TS; Marks JR Anticancer Res; 1998; 18(4C):2919-32. PubMed ID: 9713486 [TBL] [Abstract][Full Text] [Related]